CN1816350B - 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗 - Google Patents

带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗 Download PDF

Info

Publication number
CN1816350B
CN1816350B CN038166593A CN03816659A CN1816350B CN 1816350 B CN1816350 B CN 1816350B CN 038166593 A CN038166593 A CN 038166593A CN 03816659 A CN03816659 A CN 03816659A CN 1816350 B CN1816350 B CN 1816350B
Authority
CN
China
Prior art keywords
composition
chitosan
antigen
antigens
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN038166593A
Other languages
English (en)
Chinese (zh)
Other versions
CN1816350A (zh
Inventor
G·德尔古迪斯
B·宝德纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEIDEN UNIV
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron SRL
Leiden University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0302218.3A external-priority patent/GB0302218D0/en
Application filed by Chiron SRL, Leiden University filed Critical Chiron SRL
Publication of CN1816350A publication Critical patent/CN1816350A/zh
Application granted granted Critical
Publication of CN1816350B publication Critical patent/CN1816350B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN038166593A 2002-05-14 2003-05-14 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗 Expired - Fee Related CN1816350B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38067502P 2002-05-14 2002-05-14
US60/380,675 2002-05-14
GB0302218.3 2003-01-30
GBGB0302218.3A GB0302218D0 (en) 2003-01-30 2003-01-30 Vaccine formulation & Mucosal delivery
PCT/IB2003/002382 WO2003094834A2 (en) 2002-05-14 2003-05-14 Mucosal vaccines with chitosan adjuvant and meningococcal antigens

Publications (2)

Publication Number Publication Date
CN1816350A CN1816350A (zh) 2006-08-09
CN1816350B true CN1816350B (zh) 2010-11-10

Family

ID=29420626

Family Applications (2)

Application Number Title Priority Date Filing Date
CN038166593A Expired - Fee Related CN1816350B (zh) 2002-05-14 2003-05-14 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗
CN038166585A Expired - Fee Related CN1684707B (zh) 2002-05-14 2003-05-14 用于细菌性脑膜炎的粘膜结合疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN038166585A Expired - Fee Related CN1684707B (zh) 2002-05-14 2003-05-14 用于细菌性脑膜炎的粘膜结合疫苗

Country Status (12)

Country Link
US (2) US20060147466A1 (cg-RX-API-DMAC7.html)
EP (1) EP1506007B1 (cg-RX-API-DMAC7.html)
JP (2) JP4662537B2 (cg-RX-API-DMAC7.html)
CN (2) CN1816350B (cg-RX-API-DMAC7.html)
AT (1) ATE513560T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003239744B2 (cg-RX-API-DMAC7.html)
BR (1) BR0310042A (cg-RX-API-DMAC7.html)
CA (1) CA2485999C (cg-RX-API-DMAC7.html)
MX (1) MXPA04011248A (cg-RX-API-DMAC7.html)
NZ (1) NZ536859A (cg-RX-API-DMAC7.html)
RU (1) RU2378008C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003094960A2 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
AU2011224064A1 (en) * 2003-10-02 2011-10-06 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
EP2269638A3 (en) * 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008101349A1 (en) 2007-02-23 2008-08-28 Her Majesty The Queen, In Right Of Canada, As Repesented By The Minister Of National Defence Recombinant viral vectors for prevention and protection against alphavirus infection
CN101249261B (zh) * 2008-03-18 2010-10-27 中国疾病预防控制中心病毒病预防控制所 一种肾综合征出血热粘膜免疫疫苗及其制备方法
EP2440251A4 (en) * 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
RU2632651C2 (ru) 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
CN104383531A (zh) * 2014-11-18 2015-03-04 北京智飞绿竹生物制药有限公司 预防儿童脑膜炎的联合疫苗及其制备方法
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN105031644A (zh) * 2015-06-25 2015-11-11 中国科学院过程工程研究所 一种疫苗佐剂及含该疫苗佐剂的疫苗组合物和疫苗制剂
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
RU2704452C1 (ru) * 2019-04-22 2019-10-28 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения вакцины гемофильной тип b конъюгированной
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3185429A1 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Bacterial immunization using nanoparticle vaccine
US12053515B2 (en) 2020-08-10 2024-08-06 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE69939943D1 (de) * 1998-10-21 2009-01-02 Kitasato Inst Attenuierte Toxine als Adjuvantien
CA2366152A1 (en) * 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
JP3980884B2 (ja) * 2000-02-15 2007-09-26 アイディー バイオメディカル コーポレイション オブ ケベック プロテオソーム・インフルエンザ・ワクチン
US20020009463A1 (en) * 2000-02-23 2002-01-24 Jan Raa Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
EP1946769B1 (en) * 2000-06-29 2012-05-30 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
ES2399386T3 (es) * 2001-04-05 2013-04-01 Novartis Vaccines And Diagnostics, Inc. Aumento de la inmunidad de las mucosas tras sensibilización parenteral
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
ES2339762T3 (es) * 2002-01-14 2010-05-25 Novartis Vaccines And Diagnostics, Inc. Vacuna contra el vih y procedimiento de uso.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ILLUM L ET AL.CHITOSAN AS A NOVEL NASAL DELIVERY SYSTEMFOR VACCINES.ADVANCED DRUG DELIVERY REVIEWS1-3 51.2001,1-3(51),81-96.
ILLUM L ET AL.CHITOSAN AS A NOVEL NASAL DELIVERY SYSTEMFOR VACCINES.ADVANCED DRUG DELIVERY REVIEWS1-3 51.2001,1-3(51),81-96. *
VAN DER LUBBEN INEZ M ET AL.CHITOSAN AND ITS DERIVATIVES IN MUCOSAL DRUGAND VACCINE DELIVERY.EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES14 3.2001,14(3),201-207.
VAN DER LUBBEN INEZ M ET AL.CHITOSAN AND ITS DERIVATIVES IN MUCOSAL DRUGAND VACCINE DELIVERY.EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES14 3.2001,14(3),201-207. *
WO 0200249 A,全文.

Also Published As

Publication number Publication date
WO2003094960A3 (en) 2004-03-04
MXPA04011248A (es) 2005-02-17
US20060147466A1 (en) 2006-07-06
CA2485999C (en) 2015-02-17
CN1816350A (zh) 2006-08-09
BR0310042A (pt) 2005-04-05
US20110159030A1 (en) 2011-06-30
CA2485999A1 (en) 2003-11-20
AU2003239744A1 (en) 2003-11-11
AU2003239744B2 (en) 2008-07-03
RU2004136295A (ru) 2006-03-20
JP2010202672A (ja) 2010-09-16
EP1506007A2 (en) 2005-02-16
EP1506007B1 (en) 2011-06-22
JP4662537B2 (ja) 2011-03-30
NZ536859A (en) 2007-11-30
ATE513560T1 (de) 2011-07-15
CN1684707A (zh) 2005-10-19
JP2005526847A (ja) 2005-09-08
CN1684707B (zh) 2012-09-05
WO2003094960A2 (en) 2003-11-20
RU2378008C2 (ru) 2010-01-10

Similar Documents

Publication Publication Date Title
CN100579580C (zh) 粘膜脑膜炎球菌疫苗
US20110150923A1 (en) Mucosal meningococcal vaccines
CN100482273C (zh) 溶解和结合荚膜多糖的疫苗
EP1506007B1 (en) Mucosal combination vaccines for bacterial meningitis
EP1409013B1 (en) Vaccines comprising aluminium adjuvants and histidine
USRE45587E1 (en) Vaccines comprising aluminum adjuvants and histidine
US20060008476A1 (en) Adjuvanted antigenic meningococcal compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP01 Change in the name or title of a patent holder

Address after: Leiden

Co-patentee after: Novartis Vaccines & Diagnostic

Patentee after: Leiden Univ.

Address before: Leiden

Co-patentee before: Chiron S. P. A.

Patentee before: Leiden Univ.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101110

Termination date: 20170514

CF01 Termination of patent right due to non-payment of annual fee